PROK · Prokidney Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $33.84M | - | $26.82M | $25.88M | $27.26M | - | $31.25M | $29.40M | $27.23M | - |
| SG&A | $11.32M | - | $11.94M | $14.05M | $14.36M | - | $17.72M | $13.65M | $12.84M | - |
| Total Operating Expenses | $45.16M | - | $38.76M | $39.93M | $41.62M | - | $48.97M | $43.06M | $40.08M | - |
| D&A | $1.66M | - | $1.40M | $1.49M | $1.60M | - | $1.20M | $964.0K | $1.10M | - |
| Operating Income | ($44.93M) | - | ($38.54M) | ($39.71M) | ($41.39M) | - | ($48.97M) | ($43.06M) | ($40.08M) | - |
| Interest Expense | $15.0K | - | $2.0K | $1.0K | $0 | - | $2.0K | $3.0K | $2.0K | - |
| Income Tax | $0 | - | $560.0K | $848.0K | $591.0K | - | ($2.34M) | ($56.0K) | $98.0K | - |
| Net Income | ($20.04M) | - | ($16.47M) | ($16.55M) | ($16.73M) | - | ($17.91M) | ($12.51M) | ($9.49M) | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $101.89M | $108.54M | $95.32M | $84.94M | $97.81M | $99.12M | $108.09M | $214.51M | $84.39M | $60.65M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.59M | $940.0K | $1.94M | $2.44M | $3.12M | $3.63M | $2.85M | $2.93M | $3.38M | $5.10M |
| Current Assets | $234.90M | $280.68M | $299.99M | $324.44M | $359.66M | $395.88M | $430.23M | $450.26M | $340.16M | $374.15M |
| Total Assets | $292.78M | $335.57M | $351.61M | $372.13M | $406.06M | $441.07M | $474.79M | $499.16M | $387.76M | $420.55M |
| Current Liabilities | $25.93M | $30.74M | $29.06M | $28.26M | $32.81M | $36.22M | $25.18M | $20.59M | $19.30M | $25.04M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $29.68M | $34.78M | $33.27M | $32.68M | $36.08M | $39.44M | $31.32M | $26.80M | $24.73M | $29.22M |
| Stockholders' Equity | ($1.02B) | ($1.01B) | ($1.01B) | ($1.00B) | ($998.55M) | ($994.95M) | ($979.71M) | ($972.37M) | ($1.10B) | ($1.10B) |
| Retained Earnings | ($1.29B) | ($1.27B) | ($1.25B) | ($1.23B) | ($1.22B) | ($1.20B) | ($1.18B) | ($1.16B) | ($1.15B) | ($1.14B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($41.68M) | - | - | - | ($29.59M) | - | - | - | ($34.65M) | - |
| Investing Cash Flow | $34.83M | - | - | - | $28.29M | - | - | - | $58.40M | - |
| Financing Cash Flow | $215.0K | - | - | - | ($12.0K) | - | - | - | ($13.0K) | - |
| CapEx | $3.79M | - | - | - | $1.14M | - | - | - | $960.0K | - |
| Free Cash Flow | ($45.47M) | - | - | - | ($30.73M) | - | - | - | ($35.61M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 2.27 | - | - | - | 1.84 | - | - | - | 3.75 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.8% | - | -4.7% | -4.4% | -4.1% | - | -3.8% | -2.5% | -2.4% | - |
| Return on equity | 2.0% | - | 1.6% | 1.7% | 1.7% | - | 1.8% | 1.3% | 0.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 9.06 | 9.13 | 10.32 | 11.48 | 10.96 | 10.93 | 17.09 | 21.87 | 17.62 | 14.94 |
| Quick ratio | 9.06 | 9.13 | 10.32 | 11.48 | 10.96 | 10.93 | 17.09 | 21.87 | 17.62 | 14.94 |
| Cash ratio | 3.93 | 3.53 | 3.28 | 3.01 | 2.98 | 2.74 | 4.29 | 10.42 | 4.37 | 2.42 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -2995.5x | - | -19269.5x | -39709.0x | - | - | -24486.5x | -14352.0x | -20038.0x | - |
| Equity multiplier | -0.29 | -0.33 | -0.35 | -0.37 | -0.41 | -0.44 | -0.48 | -0.51 | -0.35 | -0.38 |
| Liabilities / Assets | 0.10 | 0.10 | 0.09 | 0.09 | 0.09 | 0.09 | 0.07 | 0.05 | 0.06 | 0.07 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -8.6% | - | 21.3% | 7.8% | -3.3% | - | -5.1% | -8.1% | 2.0% | - |
| Net income growth (YoY) | -19.7% | - | 8.0% | -32.4% | -76.3% | - | -63.1% | -37.2% | 74.3% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -48.0% | - | - | - | 13.7% | - | - | - | -32.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -2.5% | -1.6% | -2.9% | -3.1% | 8.9% | 9.8% | 10.3% | 26.5% | 31.6% | -0.6% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing PROKIDNEY CORP. against the 5 most active filers in the same SIC group.